Cited by 383Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatmentsDiabetes Treatment and Management

The DOI matches its Crossref record; 255 of the 258 references it cites were found in a registry or an index.

The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

Open access

Athauda, Dilan, Foltynie, Thomas·2016·Drug Discovery Today

DOI 10.1016/j.drudis.2016.01.013

Open this paper in CoChat — free account Open PDF

Abstract

Growing evidence suggests that agonists of the glucagon-like peptide 1 (GLP-1) receptor provide neuroprotection across a range of experimental models of Parkinson's disease (PD) and, recently, a small proof-of-concept, open-label human trial of exenatide in the treatment moderate severity PD appeared to show persistent improvements in motor and cognitive function. The underlying mechanisms of action remain unclear, but as evidence for the potential use of GLP-1 agonists in treating several neurodegenerative disease mounts, and with several clinical trials of GLP-1 analogues in PD and Alzheimer's disease (AD) currently underway, here we review the molecular mechanisms underlying the neuroprotective effects of GLP-1 analogues in the laboratory and their potential therapeutic utility with particular relevance to PD and PD dementia (PDD).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2016.01.013

Cites

255 of 255 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

2 retracted

SIRT1 Protects against α-Synuclein Aggregation by Activating Molecular Chaperones
Dönmez, G., Arun, A., Chung, C. Y., McLean, P. J., Lindquist, S. L., & Guarente, L. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.3442-11.2012 · Cited by 208 · cited 1×
“122 Donmez, G. and Outeiro, T.F. (2013) SIRT1 and SIRT2: emerging targets in”
Retracted
RETRACTED: Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson’s disease with combined noradrenergic and serotonergic lesions
Rampersaud, N., Harkavyi, A., Giordano, G., Lever, R., Whitton, J., & Whitton, P. S. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.07.004 · Cited by 32 · cited 1×
“202, 431–439 21 Rampersaud, N. et al. (2012) Exendin-4 reverses biochemical and behavioral”
Retracted
Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · cited 1×
“17, 485–492 104 Lagouge, M. et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha.”
Background
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
A central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359 · cited 1×
“202 Hirosumi, J. et al. (2002) A central role for JNK in obesity and insulin resistance.”
Background
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., ADENA, M. A., Halliday, G. M., & Morris, J. G. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,346
Crosstalk in NF-κB Signaling Pathways
Oeckinghaus, A., Hayden, M. S., & Ghosh, S. (2011) · Nature Immunology · doi:10.1038/ni.2065 · Cited by 1,942
PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624
Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus
Zhao, C., Teng, E. M., Summers, R. G., Ming, G.-L., & Gage, F. H. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3648-05.2006 · Cited by 1,257 · cited 2×
“132 Zhao, C. et al. (2006) Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J. Neurosci. 26, 3–11 133 Höglinger, G.U. et al. (2004) Dopamine depletion impairs precursor cell proliferation in Parkinson disease.”
Background
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort
Williams‐Gray, C. H., Evans, J., Goris, A., Foltynie, T., Ban, M., Robbins, T. W., Brayne, C., Kolachana, B. S., Weinberger, D. R., Sawcer, S. J., et al. (2009) · Brain · doi:10.1093/brain/awp245 · Cited by 1,017
Self-citation
Cognitive profile of patients with newly diagnosed Parkinson disease
Muslimović, D., Post, B., Speelman, J. D., & Schmand, B. (2005) · Neurology · doi:10.1212/01.wnl.0000180516.69442.95 · Cited by 1,007 · cited 1×
“190 Muslimovic, D. et al. (2005) Cognitive profile of patients with newly diagnosed Parkinson disease.”
Background
Dopamine depletion impairs precursor cell proliferation in Parkinson disease
Höglinger, G. U., Rizk, P., Mp, M., Duyckaerts, C. J., Oertel, W. H., Caillé, I., & Hirsch, É. C. (2004) · Nature Neuroscience · doi:10.1038/nn1265 · Cited by 974 · cited 1×
“138 Luciani, P. et al. (2010) Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model.”
Background
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
Irwin, D. J., Lee, V. M. ‐., & Trojanowski, J. Q. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3549 · Cited by 914
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Microglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 869 · cited 1×
“2012, 271732 51 Ouchi, Y. et al. (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease.”
Background
PGC-1 α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease
Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., Eklund, A. C., Zhang‐James, Y., Kim, P. D., Hauser, M. A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001059 · Cited by 868
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers
Bomfim, T. R., Forny‐Germano, L., Sathler, L. B., Brito‐Moreira, J., Houzel, J., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 849
Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH
Zhang, G., Li, J., Purkayastha, S., Tang, Y., Zhang, H., Yin, Y., Li, B., Liu, G., & Cai, D. (2013) · Nature · doi:10.1038/nature12143 · Cited by 834 · cited 1×
“Neuroscience 170, 1239–1248 28 Han, W-N. et al. (2013) Liraglutide protects against amyloid-b protein-induced impairment of spatial learning and memory in rats.”
Background
Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease
Petzinger, G. M., Fisher, B. E., McEwen, S., Beeler, J. A., Walsh, J. P., & Jakowec, M. W. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70123-6 · Cited by 798
Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791
The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort
Williams‐Gray, C. H., Mason, S., Evans, J., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. A. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305277 · Cited by 683
Self-citation
Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson disease
Hunot, S., Brugg, B., Ricard, D., Michel, P. P., Muriel, M., Ruberg, M., Faucheux, B. A., Agid, Y., & Hirsch, É. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7531 · Cited by 678 · cited 3×
“Diabetes 59, 1030–1037 68 Hunot, S. et al. (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 94, 7531–7536 69 Ghosh, A. et al. (2007) Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mo…”
BackgroundInfluential
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 645
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645 · cited 2×
“250 Finan, B. et al. (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med. 5 209ra151 251 Ji, C. et al. (2015) A novel dual GLP-1 and GIP receptor agonist is neuroprotective in”
Background
Mash1regulates neurogenesis in the ventral telencephalon
Casarosa, S., Schuurmans, C. J., & Guillemot, F. (1999) · Development · doi:10.1242/dev.126.3.525 · Cited by 639
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
Compta, Y., Parkkinen, L., O’Sullivan, S. S., Vandrovcová, J., Holton, J. L., Collins, C., Lashley, T., Kallis, C., Williams, D. R., de Silva, R., et al. (2011) · Brain · doi:10.1093/brain/awr031 · Cited by 607 · cited 2×
“109 Compta, Y. et al. (2011) Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain 134, 1493–1505 110 Qin, Z.”
Background
β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease
Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., & Mucke, L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211412398 · Cited by 607
GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK
Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Fernø, J., Salvador, J., Escalada, J., et al. (2014) · Diabetes · doi:10.2337/db14-0302 · Cited by 602 · cited 1×
“Nutrition 26, 243–249 214 Beiroa, D. et al. (2014) GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.”
Background
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 10×
“93 Li, Z. et al. (2013) Exendin-4 protects mitochondria from reactive oxygen species induced apoptosis in pancreatic Beta cells. PLOS ONE 8, e76172 94 Zheng, B. et al. (2010) PGC-1a, a potential therapeutic target for early intervention in Parkinson’s disease. Sci. Transl. Med. 2 52ra73 95 Clark, J. et al. (2011) Asso…”
BackgroundInfluential
Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.
Perry, E. K., Curtis, M., Dick, D. J., Candy, J., Atack, J. R., Bloxham, C. A., Blessed, G., FAIRBAIRN, A. F., Tomlinson, B. E., & Perry, R. H. (1985) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.5.413 · Cited by 572
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study
Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
Cortical Cholinergic Function Is More Severely Affected in Parkinsonian Dementia Than in Alzheimer Disease
Bohnen, N. I., Kaufer, D., Ivanco, L. S., Lopresti, B. J., Koeppe, R. A., Davis, J. G., Mathis, C. A., Moore, R. Y., & DeKosky, S. T. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1745 · Cited by 561
Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis
Qiu, W. Q., & Folstein, M. F. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.01.004 · Cited by 557
Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529 · cited 2×
“Lancet 381, 117–124 246 Aviles-Olmos, I. et al. (2013) Exenatide and the treatment of patients with Parkinson’s disease.”
BackgroundSelf-citation
α-Synuclein Is Localized to Mitochondria-Associated ER Membranes
Guardia-Laguarta, C., Area-Gomez, E., Rüb, C., Liu, Y., Magrané, J., Becker, D., Voos, W., Schon, E. A., & Przedborski, S. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.2507-13.2014 · Cited by 515
SIRT1 in Neurodevelopment and Brain Senescence
Herskovits, A. Z., & Guarente, L. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.028 · Cited by 504
Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
Neurons Regulate Extracellular Levels of Amyloid β-Protein via Proteolysis by Insulin-Degrading Enzyme
Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D. M., Hartley, D. M., Chesneau, V., Rosner, M. R., & Selkoe, D. J. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-05-01657.2000 · Cited by 498 · cited 1×
“Aging 27, 190–198 129 Vekrellis, K. et al. (2000) Neurons regulate extracellular levels of amyloid”
Background
Insulin resistance in brain alters dopamine turnover and causes behavioral disorders
Kleinridders, A., Cai, W., Cappellucci, L., Ghazarian, A., Collins, W. R., Vienberg, S. G., Pothos, E. N., & Kahn, C. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500877112 · Cited by 486 · cited 1×
“38, 806–816 201 Kleinridders, A. et al. (2015) Insulin resistance in brain alters dopamine turnover and causes behavioral disorders.”
Background
Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain
Cork, S. C., Richards, J. E., Holt, M. K., Gribble, F. M., Reimann, F., & Trapp, S. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.07.008 · Cited by 478 · cited 8×
“Neurochem. 93, 105–117 233 Kim, S.R. et al. (2011) Age and a-synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signaling.”
BackgroundInfluential
Pathological changes in the nucleus of meynert in Alzheimer's and Parkinson's diseases
Candy, J., Perry, R. H., Perry, E. K., Irving, D., Blessed, G., FAIRBAIRN, A. F., & Tomlinson, B. E. (1983) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(83)90045-x · Cited by 463
Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology
Griffin, R. J., Moloney, A., Kelliher, M., Johnston, J. A., Ravid, R., Dockery, P., O'Connor, R., & O'Neill, C. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02949.x · Cited by 459
Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease
Ghosh, A., Roy, A., Liu, X., Kordower, J. H., Mufson, E. J., Hartley, D. M., Ghosh, S., Mosley, R. L., Gendelman, H. E., & Pahan, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704908104 · Cited by 438
SIRT1 and SIRT2: emerging targets in neurodegeneration
Dönmez, G., & Outeiro, T. F. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302451 · Cited by 419
Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394 · cited 1×
“11, 270 76 Kodera, R. et al. (2011) Glucagon-like peptide-1 receptor agonist ameliorates renal”
Dementia in Parkinson disease
Hilker, R., Thomas, A. V., Klein, J. C., Weisenbach, S., Kalbe, E., Burghaus, L., Jacobs, A. H., Herholz, K., & Wd, H. (2005) · Neurology · doi:10.1212/01.wnl.0000191154.78131.f6 · Cited by 387
Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380
Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia
Bohnen, N. I., Kaufer, D. I., Hendrickson, R., Ivanco, L. S., Lopresti, B. J., Constantine, G. M., Mathis, C. A., Davis, J. G., Moore, R. Y., & DeKosky, S. T. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0971-0 · Cited by 364
Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease
Ferreira, S. T., Clarke, J. R., Bomfim, T. R., & Felice, F. G. D. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.010 · Cited by 363
Entry of exendin-4 into brain is rapid but may be limited at high doses
Kastin, A. J., & Akerstrom, V. L. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 358
Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron
Perry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10611 · Cited by 347
Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease
Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345 · cited 1×
“106, 1285–1290 19 Bertilsson, G. et al. (2008) Peptide hormone exendin-4 stimulates subventricular”
Insulin in Central Nervous System: More than Just a Peripheral Hormone
Duarte, A. I., Moreira, P. I., & Oliveira, C. R. (2012) · Journal of Aging Research · doi:10.1155/2012/384017 · Cited by 337
How does brain insulin resistance develop in Alzheimer's disease?
De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337
Pathogenesis of Parkinson's disease
Hirsch, E. C., Jenner, P., & Przedborski, S. (2013) · Movement Disorders · doi:10.1002/mds.25032 · Cited by 336
Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?
Tayebi, N. (2003) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(03)00071-4 · Cited by 333 · cited 2×
“com 224 Tayebi, N. et al. (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol.”
Background
GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease
Li, Y., Duffy, K. B., Ottinger, M. A., Ray, B., Bailey, J. A., Holloway, H. W., Tweedie, D., Perry, T., Mattson, M. P., Kapogiannis, D., et al. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1314 · Cited by 323
Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
The expression of GLP‐1 receptor mRNA and protein allows the effect of GLP‐1 on glucose metabolism in the human hypothalamus and brainstem
Álvarez, E., Martínez, M. D., Roncero, I., Chowen, J. A., Cuartero, B. G., Gispert, J. D., Sanz, C., Vázquez, P., Maldonado, A., Cáceres, J. D., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02914.x · Cited by 307 · cited 1×
“Endocrinology 156, 255–267 5 Alvarez, E. et al. (2005) The expression of GLP-1 receptor mRNA and protein allows”
Background
A Novel Neurotrophic Property of Glucagon-Like Peptide 1: A Promoter of Nerve Growth Factor-Mediated Differentiation in PC12 Cells
Perry, T., Lahiri, D. K., Chen, D., Zhou, J., Shaw, K. T. Y., Egan, J. M., & Greig, N. H. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.958 · Cited by 303
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
Avilés-Olmos, I., Dickson, J. C., Kefalopoulou, Z. M., Djamshidian, A., Kahan, J., Ell, P. J., Whitton, P. S., Wyse, R. K. H., Isaacs, T., Lees, A. J., et al. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-140364 · Cited by 300
Self-citation
PI3-kinase/Akt/mTOR signaling: Impaired on/off switches in aging, cognitive decline and Alzheimer's disease
Neill, C. O. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.02.025 · Cited by 300 · cited 1×
“241 O’ Neill, C. (2013) PI3-kinase/Akt/mTOR signaling: impaired on/off switches in”
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease
Harkavyi, A., Abuirmeileh, A. N., Lever, R., Kingsbury, A. E., Biggs, C. S., & Whitton, P. S. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-19 · Cited by 294 · cited 2×
“13, 33 17 Harkavyi, A. et al. (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease. J. Neuroinflammation 5, 19 18 Li, Y. et al. (2009) GLP-1 receptor stimulation preserves primary cortical and”
Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease
Jellinger, K. A., Seppi, K., Wenning, G. K., & Poewe, W. H. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200027 · Cited by 287
Synaptic Dysfunction in Parkinson’s Disease
Picconi, B., Piccoli, G., & Calabresi, P. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-3-7091-0932-8_24 · Cited by 286
Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease
Abbas, T. F., Faivre, É., & Hölscher, C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.035 · Cited by 285
Effects of proinflammatory cytokines on the growth, fate, and motility of multipotential neural precursor cells
Ben‐Hur, T., Menachem-Zidon, O. B., Furer, V. L., Einstein, O., Mizrachi‐Kol, R., & Grigoriadis, N. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00218-5 · Cited by 283 · cited 1×
“PLOS ONE 9, e89229 155 Ben-Hur, T. et al. (2003) Effects of proinflammatory cytokines on the growth, fate, and motility of multipotential neural precursor cells.”
Background
Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease
Golpich, M., Amini, E., Hemmati, F., Ibrahim, N. M., Rahmani, B., Mohamed, Z., Raymond, A. A., Dargahi, L., Ghasemi, R., & Ahmadiani, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.010 · Cited by 282
α‐Synuclein contributes to GSK‐3β‐catalyzed Tau phosphorylation in Parkinson's disease models
Duka, T., Duka, V., Joyce, J. N., & Sidhu, A. (2009) · The FASEB Journal · doi:10.1096/fj.08-120410 · Cited by 276
Neuroprotective and neurotrophic actions of glucagon‐like peptide‐1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders
Salcedo, I., Tweedie, D., Li, Y., & Greig, N. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01971.x · Cited by 272 · cited 1×
“R e ie w s K E Y N O T E R E V IE W 139 Salcedo, I. et al. (2012) Neuroprotective and neurotrophic actions of glucagon-like”
Background
Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease
Kim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263 · cited 2×
“86, 326–338 20 Kim, S. et al. (2009) Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal”
Background
Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease
Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.054 · Cited by 246
Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study
Mielke, M. M., Maetzler, W., Haughey, N. J., Bandaru, V. V. R., Savica, R., Deuschle, C., Gasser, T., Hauser, A., Gräber‐Sultan, S., Schleicher, E. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073094 · Cited by 241
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237
Intracellular Signals Mediating the Food Intake-Suppressive Effects of Hindbrain Glucagon-like Peptide-1 Receptor Activation
Hayes, M. R., Leichner, T. M., Zhao, S., Lee, G., Chowansky, A., Zimmer, D. J., Jonghe, B. C. D., Kanoski, S. E., Grill, H. J., & Bence, K. K. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.02.001 · Cited by 234
Shared dysregulated pathways lead to Parkinson's disease and diabetes
Santiago, J. A., & Potashkin, J. A. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.01.002 · Cited by 232
RTP801 Is Induced in Parkinson's Disease and Mediates Neuron Death by Inhibiting Akt Phosphorylation/Activation
Malagelada, C., Jin, Z. H., & Greene, L. A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3928-08.2008 · Cited by 228 · cited 1×
“234 Malagelada, C. et al. (2008) RTP801 is induced in Parkinson’s disease and mediates neuron death by inhibiting Akt phosphorylation/activation.”
Background
Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening
Koole, C., Wootten, D. L., Simms, J., Valant, C., Sridhar, R., Woodman, O. L., Miller, L. J., Summers, R. J., Christopoulos, A., & Sexton, P. M. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065664 · Cited by 225 · cited 1×
“013 255 Koole, C. et al. (2010) Allosteric ligands of the glucagon-like peptide 1 receptor”
Background
Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE ‐ NF κB and Nrf2‐antioxidant signaling pathways
Abdelsalam, R. M., & Safar, M. M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13087 · Cited by 224
In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease
Iannaccone, S., Cerami, C., Alessio, M., Garibotto, V., Panzacchi, A., Olivieri, S., Gelsomino, G., Moresco, R. M., & Perani, D. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.07.002 · Cited by 221 · cited 1×
“52 Iannaccone, S. et al. (2013) In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson’s disease.”
Background
New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease
Calabresi, P., Castrioto, A., Filippo, M. D., & Picconi, B. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70118-2 · Cited by 216
Involvement of Akt in neurite outgrowth
Read, D. E., & Gorman, A. M. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0057-8 · Cited by 213
Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia
Fan, Z., Aman, Y., Ahmed, I., Chetelat, G., Landeau, B., Ray Chaudhuri, K., Brooks, D. J., & Edison, P. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.016 · Cited by 212 · cited 5×
“84 Fan, Y. et al. (2014) Exendin-4 protects retinal cells from early diabetes in Goto-”
BackgroundInfluential
Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain
Hamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210 · cited 1×
“12, 891–899 33 Hamilton, A. et al. (2011) Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain.”
Background
M1 and M2 immune activation in Parkinson’s Disease: Foe and ally?
Moehle, M. S., & West, A. B. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.11.018 · Cited by 209
Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells
Wang, Q., Li, L., Xu, E., Wong, V. S. C., Rhodes, C. J., & Brubaker, P. L. (2004) · Diabetologia · doi:10.1007/s00125-004-1327-5 · Cited by 209
Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF
O’Keeffe, G. C., Tyers, P., Aarsland, D., Dalley, J. W., Barker, R. A., & Caldwell, M. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803955106 · Cited by 207
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. J. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/eoid.12.1.87.21250 · Cited by 204
Pathologic Accumulation of α-Synuclein and Aβ in Parkinson Disease Patients With Dementia
Kotzbauer, P. T., Cairns, N. J., Campbell, M. C., Willis, A. W., Racette, B. A., Tabbal, S. D., & Perlmutter, J. S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1608 · Cited by 200
Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Provides Neuroprotection in Mice Transient Focal Cerebral Ischemia
Teramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., & Urabe, T. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.51 · Cited by 199 · cited 2×
“013 56 Teramoto, S. et al. (2011) Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia.”
Background
Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca mulatta) Brain
Heppner, K. M., Kirigiti, M. A., Secher, A., Paulsen, S. J., Buckingham, R., Pyke, C., Knudsen, L. B., Vrang, N., & Grove, K. L. (2014) · Endocrinology · doi:10.1210/en.2014-1675 · Cited by 195
The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer’s Disease
Hansen, H. H., Fabricius, K., Barkholt, P., Niehoff, M. L., Morley, J. E., Jelsing, J., Pyke, C., Knudsen, L. B., Farr, S. A., & Vrang, N. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143090 · Cited by 193
Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease
McClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.023 · Cited by 193
Akt signal transduction dysfunction in Parkinson's disease
Timmons, S., Coakley, M. F., Moloney, A. M., & Neill, C. O. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.09.055 · Cited by 192 · cited 1×
“31, 969–978 230 Timmons, S. et al. (2009) Akt signal transduction dysfunction in Parkinson’s”
Background
Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease
Kosaraju, J., Gali, C. C., Khatwal, R. B., Dubala, A., Chinni, S., Holsinger, R. M. D., Madhunapantula, S. V., Nataraj, S. K. M., & Basavan, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.008 · Cited by 191
Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson’s Disease?
Leal, M. C., Casabona, J. C., Puntel, M., & Pitossi, F. J. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00053 · Cited by 181
[11C]-PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?
Bartels, A. L., Willemsen, A. T. M., Doorduin, J., de Vries, E. F. J., Dierckx, R. A., & Leenders, K. L. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.05.005 · Cited by 181
Microglial Activation and Antioxidant Responses Induced by the Parkinson’s Disease Protein α-Synuclein
Béraud, D., Hathaway, H. A., Trecki, J., Chasovskikh, S., Johnson, D. A., Johnson, J. A., Federoff, H. J., Shimoji, M., Mhyre, T. R., & Maguire‐Zeiss, K. A. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9401-0 · Cited by 179 · cited 1×
“disease: a role for inflammation and immunomodulation? Neuroimmunomodulation 21, 88–94 46 Béraud, D. et al. (2013) Microglial activation and antioxidant responses induced by the Parkinson’s disease protein a-synuclein.”
Background
Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease
Xu, Y., Liu, C., Chen, S., Ye, Y., Guo, M., Ren, Q., Liu, L., Zhang, H., Xu, C., Zhou, Q., et al. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.04.009 · Cited by 170
Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms
Kumar, P., Padi, S. S., Naidu, P. S., & Kumar, A. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00014 · Cited by 167 · cited 1×
“Neuron 81, 471–483 103 Kumar, P. et al. (2006) Effect of resveratrol on 3-nitropropionic acid-induced”
Background
Neural and Immune Mechanisms in the Pathogenesis of Parkinson’s Disease
Blandini, F. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9435-y · Cited by 165 · cited 1×
“47 Blandini, F. (2013) Neural and immune mechanisms in the pathogenesis of”
Background
Neurodegeneration in an animal model of Parkinson’s disease is exacerbated by a high-fat diet
Morris, J. K., Bomhoff, G. L., Stanford, J. A., & Geiger, P. C. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00449.2010 · Cited by 163
Platelet-Derived Growth Factor (PDGF-BB) and Brain-Derived Neurotrophic Factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions
Mohapel, P., Frielingsdorf, H., Häggblad, J., Zachrisson, O., & Brundin, P. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.11.056 · Cited by 163
Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice
Gengler, S., McClean, P. L., McCurtin, R. E., Gault, V. A., & Hölscher, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.02.014 · Cited by 161 · cited 2×
“1473, 204–213 26 Gengler, S. et al. (2012) Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice.”
Background
GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid
Gault, V. A., & Hölscher, C. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.025 · Cited by 159
The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-β Plaque and Glial Pathology in a Mouse Model of Alzheimer’s Disease
Long-Smith, C. M., Manning, S., McClean, P. L., Coakley, M. F., O’Halloran, D., Hölscher, C., & O’Neill, C. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8199-5 · Cited by 158
The extra‐pancreatic effects of GLP‐1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice
D’Amico, M., Filippo, C. D., Marfella, R., Abbatecola, A. M., Ferraraccio, F., Rossi, F., & Paolisso, G. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.12.004 · Cited by 156
Insulin resistance impairs nigrostriatal dopamine function
Morris, J. K., Bomhoff, G. L., Gorres, B. K., Davis, V. A., Kim, J., Lee, P., Brooks, W. M., Gerhardt, G. A., Geiger, P. C., & Stanford, J. A. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.06.005 · Cited by 155
Neurotrophic factor therapy for Parkinson’s disease
Rangasamy, S. B., Soderstrom, K. E., Bakay, R. A. E., & Kordower, J. H. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84013-0 · Cited by 155
Neuroprotective properties of GLP-1: theoretical and practical applications
Holst, J. J., Burcelin, R., & Nathanson, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.549466 · Cited by 154
Hepatic Ceramide May Mediate Brain Insulin Resistance and Neurodegeneration in Type 2 Diabetes and Non-alcoholic Steatohepatitis
Lyn‐Cook, L. E., Lawton, M., Tong, M., Silbermann, E., Longato, L., Jiao, P., Mark, P., Wands, J. R., Xu, H., & de la Monte, S. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0984 · Cited by 154
Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease
Abbott, S. K., Li, H., Muñoz, S. S., Knoch, B., Batterham, M. J., Murphy, K. E., Halliday, G. M., & Garner, B. (2013) · Movement Disorders · doi:10.1002/mds.25729 · Cited by 153
The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test
Isacson, R., Nielsen, E. I., Dannaeus, K., Bertilsson, G., Patrone, C., Zachrisson, O., & Wikström, L. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.008 · Cited by 153 · cited 1×
“23, 4256–4565 141 Isacson, R. et al. (2011) The glucagon-like peptide 1 receptor agonist exendin-4”
Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease
Kosaraju, J., Murthy, V., Khatwal, R. B., Dubala, A., Chinni, S., Nataraj, S. K. M., & Basavan, D. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12148 · Cited by 152
Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease
Bouchard, T. P., Malykhin, N. V., Martin, W. R. W., Hanstock, C. C., Emery, D. J., Fisher, N., & Camicioli, R. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.002 · Cited by 152
Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary‐induced obesity and insulin resistance
Porter, D. W., Kerr, B. D., Flatt, P. R., Hölscher, C., & Gault, V. A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01259.x · Cited by 150
Expression analysis of dopaminergic neurons in Parkinson’s disease and aging links transcriptional dysregulation of energy metabolism to cell death
Elstner, M., Morris, C. M., Heim, K., Bender, A., Mehta, D., Jaros, E., Klopstock, T., Meitinger, T., Turnbull, D. M., & Prokisch, H. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0828-9 · Cited by 150 · cited 1×
“467, 30–35 231 Elstner, M. et al. (2011) Expression analysis of dopaminergic neurons in”
Background
Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling
Challa, T. D., Beaton, N., Arnold, M., Rudofsky, G., Langhans, W., & Wolfrum, C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.310342 · Cited by 149
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson’s disease
Costa, C., Sgobio, C., Siliquini, S., Tozzi, A., Tantucci, M., Ghiglieri, V., Filippo, M. D., Pendolino, V., de Iure, A., Marti, M., et al. (2012) · Brain · doi:10.1093/brain/aws101 · Cited by 149 · cited 1×
“Brain 132, 2958–2969 177 Costa, C. et al. (2012) Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson’s disease.”
Background
Targeting mTOR with rapamycin: One dose does not fit all
Foster, D. A., & Toschi, A. (2009) · Cell Cycle · doi:10.4161/cc.8.7.8044 · Cited by 143
Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets
Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., et al. (2010) · Diabetes · doi:10.2337/db10-0689 · Cited by 143
Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats
Han, W.-N., Hölscher, C., Yuan, L., Yang, W., Wang, X., Wu, M., & Qi, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.009 · Cited by 141
Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer’s disease by exendin-4
Chen, S., Liu, A., An, F.-M., Yao, W., & Gao, X. (2011) · AGE · doi:10.1007/s11357-011-9303-8 · Cited by 136
Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease
Gallegos, S., Pacheco, C. R., Peters, C., Opazo, C., & Aguayo, L. G. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00059 · Cited by 136 · cited 1×
“8, 189–201 48 Gallegos, S. et al. (2015) Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson’s disease.”
Background
Hippocampal head atrophy predominance in Parkinson’s disease with hallucinations and with dementia
Ibarretxe‐Bilbao, N., Ramírez‐Ruiz, B., Tolosa, E., Martı́, M. J., Valldeoriola, F., Bargalló, N., & Junqué, C. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0885-8 · Cited by 134 · cited 1×
“179 Ibarretxe-Bilbao, N. et al. (2008) Hippocampal head atrophy predominance in Parkinson’s disease with hallucinations and with dementia.”
Background
Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis
Li, Y., Chigurupati, S., Holloway, H. W., Mughal, M. R., Tweedie, D., Bruestle, D. A., Mattson, M. P., Wang, Y., Harvey, B. K., Ray, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032008 · Cited by 131
Insulin receptor mRNA in the substantia nigra in Parkinson's disease.
Takahashi, M., Yamada, T., Tooyama, I., Moroo, I., Kimura, H., Yamamoto, T., & Okada, H. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12357-0 · Cited by 131
Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats
Darsalia, V., Mansouri, S., Ortsäter, H., Olverling, A., Nozadze, N., Krizhanovskii, C., Iverfeldt, K., Tracy, L. M., Grankvist, N., Sjöholm, Å., et al. (2011) · Clinical Science · doi:10.1042/cs20110374 · Cited by 130
GLP‐1 receptor agonists vs. DPP‐4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
Brunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130
Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies
Rees, K., Stowe, R. L., Patel, S., Ives, N. J., Breen, K. C., Clarke, C. E., & Ben‐Shlomo, Y. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008454 · Cited by 130
Hippocampal abnormalities and memory deficits in Parkinson disease
Carlesimo, G. A., Piras, F., Assogna, F., Pontieri, F. E., Caltagirone, C., & Spalletta, G. (2012) · Neurology · doi:10.1212/wnl.0b013e318259e1c5 · Cited by 129
Saxagliptin: A novel antiparkinsonian approach
Nassar, N. N., Al‐Shorbagy, M. Y., Arab, H. H., & Abdallah, D. M. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.007 · Cited by 123
Ciliary neurotrophic factor recruitment of glucagon‐like peptide‐1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons
Belsham, D. D., Fick, L. J., Dalvi, P. S., Centeno, M.-L., Chalmers, J. A., Lee, P. K. P., Wang, Y., Drucker, D. J., & Koletar, M. M. (2009) · The FASEB Journal · doi:10.1096/fj.09-133454 · Cited by 122
SIRT1 metabolic actions: Integrating recent advances from mouse models
Boutant, M., & Cantó, C. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.10.006 · Cited by 122
Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies
Rees, K., Stowe, R. L., Patel, S., Ives, N. J., Breen, K. C., Clarke, C. E., & Ben‐Shlomo, Y. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008454.pub2 · Cited by 122 · cited 2×
“46, 52–58 37 Rees, K. et al. (2011) Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies.”
Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner
Sharma, S., Chorell, E., Steneberg, P., Vernersson-Lindahl, E., Edlund, H., & Wittung-Stafshede, P. E. (2015) · Scientific Reports · doi:10.1038/srep12531 · Cited by 119
Ischemia‐induced changes in glucagon‐like peptide‐1 receptor and neuroprotective effect of its agonist, exendin‐4, in experimental transient cerebral ischemia
Lee, C. H., Yan, B., Yoo, K., Choi, J. H., Kwon, S., Her, S., Sohn, Y., Hwang, I. K., Cho, J. H., Kim, Y., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22596 · Cited by 118
Suppression of Nuclear Factor-κB Activation and Inflammation in Microglia by Physically Modified Saline
Khasnavis, S., Jana, A., Roy, A., Mazumder, M., Bhushan, B., Wood, T., Ghosh, S., Watson, R. L., & Pahan, K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.338012 · Cited by 117 · cited 1×
“78 Khasnavis, S. et al. (2012) Suppression of nuclear factor-kB activation and inflammation in microglia by physically modified saline.”
Background
Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
Parkes, D. G., Mace, K. F., & TRAUTMANN, M. E. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.741580 · Cited by 114
SIRT1 Mediates the Effect of GLP-1 Receptor Agonist Exenatide on Ameliorating Hepatic Steatosis
Xu, F., Li, Z., Zheng, X., Liu, H., Liang, H., Xu, H., Chen, Z., Zeng, K., & Weng, J. (2014) · Diabetes · doi:10.2337/db14-0263 · Cited by 114 · cited 2×
“436, 232–234 236 Xu, Y. et al. (2014) Activation of AMPK and inactivation of Akt result in”
Background
Beneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice
Himeno, T., Kamiya, H., Naruse, K., Harada, N., Ozaki, N., Seino, Y., Shibata, T., Kondo, M., Kato, J., Okawa, T., et al. (2011) · Diabetes · doi:10.2337/db10-1462 · Cited by 113
Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease
Chen, Y., Zhang, Y., Li, L., & Hölscher, C. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.09.029 · Cited by 112 · cited 3×
“63, 267–272 113 Chen, S. et al. (2012) Amelioration of neurodegenerative changes in cellular and”
BackgroundInfluential
Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice
Wang, X., Zhai, Y., Xu, L., Qiao, C., Sun, X., Ding, J., Lu, M., & Hu, G. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.11.001 · Cited by 112 · cited 3×
“197 Wang, L. et al. (2014) Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice.”
BackgroundInfluential
The molecular mechanism of rotenone-induced α-synuclein aggregation: Emphasizing the role of the calcium/GSK3β pathway
Yuan, Y., Yan, W.-F., Sun, J., Huang, J., Mu, Z., & Chen, N. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.11.029 · Cited by 111
Effects of Exendin-4 on bone marrow mesenchymal stem cell proliferation, migration and apoptosis in vitro
Zhou, H., Li, D., Chen, S., Xin, T., Yang, J., Zhou, Y. Y., Hu, S., Tian, F., Wang, J., & Chen, Y. (2015) · Scientific Reports · doi:10.1038/srep12898 · Cited by 110
Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction
Chen, Y.-T., Tsai, T., Yang, C.-C., Sun, C., Chang, L., Chen, H.-H., Chang, C.-L., Sung, P., Zhen, Y., Leu, S., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-270 · Cited by 109
Exenatide: a review from pharmacology to clinical practice
Gentilella, R., Bianchi, C., Rossi, A., & Rotella, C. M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01018.x · Cited by 108 · cited 1×
“8, 219–244 14 Gentilella, R. et al. (2009) Exenatide: a review from pharmacology to clinical practice.”
Background
GLP-1 secretion by microglial cells and decreased CNS expression in obesity
Kappe, C., Tracy, L. M., Patrone, C., Iverfeldt, K., & Sjöholm, Å. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-276 · Cited by 107
The PKB/FOXO switch in aging and cancer
Kloet, D. E. A., & Burgering, B. M. T. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.04.003 · Cited by 106
Central Proliferation and Neurogenesis Is Impaired in Type 2 Diabetes and Prediabetes Animal Models
Ramos‐Rodríguez, J. J., Gil, S. M., Ortiz-Barajas, O., Jiménez-Palomares, M., Perdomo, G., Cózar‐Castellano, I., Lechuga-Sancho, A. M., & García-Alloza, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089229 · Cited by 105
A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson′s disease by increasing expression of BNDF
Ji, C., Xue, G., Cao, L., Feng, P., Li, D., Li, L., Li, G., & Hölscher, C. (2015) · Brain Research · doi:10.1016/j.brainres.2015.09.035 · Cited by 103
CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease
Terrelonge, M., Marder, K. S., Weintraub, D. A., & Alcalay, R. N. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0647-x · Cited by 102 · cited 1×
“105 Terrelonge, M. et al. (2015) CSF b-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease.”
Background
Association of PGC-1alphapolymorphisms with age of onset and risk of Parkinson's disease
Clark, J., Reddy, S., Zheng, K., Betensky, R. A., & Simon, D. K. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-69 · Cited by 102
Impact of mitochondrial calcium on the coupling of metabolism to insulin secretion in the pancreatic β-cell
Wiederkehr, A., & Wollheim, C. B. (2008) · Cell Calcium · doi:10.1016/j.ceca.2007.11.004 · Cited by 102
Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model
Kohl, Z., Winner, B., Ubhi, K., Rockenstein, E., Mante, M., Münch, M., Barlow, C., Carter, T., Masliah, E., & Winkler, J. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07933.x · Cited by 101 · cited 2×
“12, 716–726 152 Kohl, Z. et al. (2012) Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model. Eur. J. Neurosci. 35, 10–19 153 Mohapel, P. et al. (2005) Platelet-derived growth factor (PDGF-BB) and brain-”
Background
Val8-glucagon-like peptide-1 protects against Aβ1–40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats
Wang, X. H., Li, L., Hölscher, C., Pan, Y. F., Chen, X. R., & Qi, J. S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.028 · Cited by 99
Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity
Choi, J., Jang, E.-H., Park, C., & Kang, J. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.12.008 · Cited by 98
Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling
Gao, S., Duan, C., Gao, G., Wang, X., & Yang, H. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.03.006 · Cited by 98 · cited 2×
“10, S76–S83 206 Gao, S. et al. (2015) Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling. Int. J. Biochem. Cell Biol. 64, 25–33 207 Bomfim, T.R. et al. (2012) An anti-diabetes agent protects the mouse brain from”
Background
Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats
Solmaz, V., Çınar, B. P., Yiğittürk, G., Çavuşoğlu, T., Taşkıran, D., & Erbaş, O. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.09.024 · Cited by 96 · cited 4×
“31, 6587–6594 64 Solmaz, V. et al. (2015) Exenatide reduces TNF-a expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. Eur. J. Pharmacol. 765, 482–487 65 Ahern, T. et al. (2013) Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a…”
BackgroundInfluential
Brain Insulin-Like Growth Factor and Neurotrophin Resistance in Parkinson's Disease and Dementia with Lewy Bodies: Potential Role of Manganese Neurotoxicity
Tong, M., Dong, M., & de la Monte, S. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0995 · Cited by 95 · cited 2×
“R eiew s K E Y N O T E R E V IE W 195 Tong, M. et al. (2009) Brain insulin-like growth factor and neurotrophin resistance”
Background
Subcutaneous Administration of Liraglutide Ameliorates Alzheimer-Associated Tau Hyperphosphorylation in Rats with Type 2 Diabetes1
Yang, Y., Zhang, J., Ma, D., Zhang, M., Hu, S., Shao, S., & Gong, C. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130491 · Cited by 92 · cited 3×
“117 Yang, Y. et al. (2013) Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes.”
BackgroundInfluential
Exendin-4 Reduces Ischemic Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization
Darsalia, V., Hua, S., Larsson, M., Mallard, C., Nathanson, D., Nyström, T., Sjöholm, Å., Johansson, M. E., & Patrone, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103114 · Cited by 92 · cited 2×
“59 Darsalia, V. et al. (2012) Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in type 2 diabetic rats.”
Background
Inhibition of IκB Kinase-β Protects Dopamine Neurons Against Lipopolysaccharide-Induced Neurotoxicity
Zhang, F., Li, Q., Flood, P. M., Shi, J., Hong, J., & Gao, H. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.165829 · Cited by 92
Glucagon‐like peptide‐1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study
Ahern, T., Tobin, A., Corrigan, M., Hogan, A. E., Sweeney, C. M., Kirby, B., & O'Shea, D. B. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04609.x · Cited by 91
Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice
Tweedie, D., Rachmany, L., Rubovitch, V., Lehrmann, E., Zhang, Y., Becker, K. G., Perez, E., Miller, J. P., Hoffer, B. J., Greig, N. H., et al. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.10.001 · Cited by 91 · cited 1×
“62 Tweedie, D. et al. (2013) Exendin-4, a glucagon-like peptide-1 receptor agonist”
Selective autophagy in the maintenance of cellular homeostasis in aging organisms
Hubbard, V. M., Valdor, R., Macián, F., & Cuervo, A. M. (2011) · Biogerontology · doi:10.1007/s10522-011-9331-x · Cited by 90
Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Reduces Alzheimer Disease-Associated Tau Hyperphosphorylation in the Hippocampus of Rats with Type 2 Diabetes
Xu, W., Yang, Y., Yuan, G., Zhu, W., Ma, D., & Hu, S. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000129 · Cited by 90
Adult Hippocampal Neurogenesis in Parkinson’s Disease: Impact on Neuronal Survival and Plasticity
Regensburger, M., Prots, I., & Winner, B. (2014) · Neural Plasticity · doi:10.1155/2014/454696 · Cited by 90 · cited 1×
“106, 8754–8759 135 Regensburger, M. et al. (2014) Adult hippocampal neurogenesis in Parkinson’s disease: impact on neuronal survival and plasticity.”
Background
Insulin resistance and gray matter volume in neurodegenerative disease
Morris, J. K., Vidoni, E. D., Perea, R. D., Rada, R. C., Johnson, D. K., Lyons, K. E., Pahwa, R., Burns, J. M., & Honea, R. A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.04.006 · Cited by 87 · cited 1×
“193 Takahashi, M. et al. (1996) Insulin receptor mRNA in the substantia nigra in Parkinson’s disease.”
Background
Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes
YANG, J., REN, J., SONG, J., LIU, F., WU, C., WANG, X., GONG, L., LI, W., XIAO, F., YAN, F., et al. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1350 · Cited by 84
Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status
Choi, S. H., Jung, T.-M., Lee, J. E., Lee, S., Sohn, Y. H., & Lee, P. H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.11.015 · Cited by 83
Glucagon-Like Peptide 1, Insulin, Sensory Neurons, and Diabetic Neuropathy
Kan, M., Guo, G., Singh, B., Singh, V., & Zochodne, D. W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182580673 · Cited by 80 · cited 1×
“768, 21–27 82 Kang, M.Y. et al. (2015) Glucagon-like peptide-1 increases mitochondrial biogenesis and function in INS-1 Rat insulinoma cells.”
Background
Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice
Lennox, R., Porter, D. W., Flatt, P. R., Hölscher, C., Irwin, N., & Gault, V. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.06.026 · Cited by 79
Association between AKT1 gene and Parkinson's disease: A protective haplotype
Xiromerisiou, G., Hadjigeorgiou, G. M., Papadimitriou, A., Katsarogiannis, E., Gourbali, V., & Singleton, A. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.03.026 · Cited by 77
Early intervention with glucagon‐like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice
Ma, D., Chen, F., Xu, W., Yue, W., Yuan, G., & Yang, Y. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13248 · Cited by 75
Selective induction of neocortical GABAergic neurons by the PDK1-Akt pathway through activation of Mash1
Oishi, K., Watatani, K., Itoh, Y., Okano, H., Guillemot, F., Nakajima, K., & Gotoh, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808400106 · Cited by 75 · cited 1×
“Development 126, 525–534 150 Oishi, K. et al. (2009) Selective induction of neocortical GABAergic neurons by the PDK1-Akt pathway through activation of Mash1.”
Background
Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice
Porter, W. D., Flatt, P. R., Hölscher, C., & Gault, V. A. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.91 · Cited by 75
Differential Effects of Proteases Involved in Intracellular Degradation of Amyloid β-Protein between Detergent-Soluble and -Insoluble Pools in CHO-695 Cells
Sudoh, S., Frosch, M. P., & Wolf, B. A. (2002) · Biochemistry · doi:10.1021/bi011193l · Cited by 73 · cited 1×
“130 Sudoh, S. et al. (2002) Differential effects of proteases involved in intracellular”
Background
Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury
Greig, N. H., Tweedie, D., Rachmany, L., Li, Y., Rubovitch, V., Schreiber, S., Chiang, Y. H., Hoffer, B. J., Miller, J. P., Lahiri, D. K., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.011 · Cited by 71
Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells
Kang, M. Y., Oh, T. J., & Cho, Y. M. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.2.216 · Cited by 70
Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats
Briyal, S., Gulati, K., & Gulati, A. (2011) · Brain Research · doi:10.1016/j.brainres.2011.10.026 · Cited by 70
Akt as a Victim, Villain and Potential Hero in Parkinson’s Disease Pathophysiology and Treatment
Greene, L. A., Levy, O., & Malagelada, C. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9671-8 · Cited by 69
Destruction of Dopaminergic Neurons in the Midbrain by 6-Hydroxydopamine Decreases Hippocampal Cell Proliferation in Rats: Reversal by Fluoxetine
Suzuki, K., Okada, K., Wakuda, T., Shinmura, C., Kameno, Y., Iwata, K., Takahashi, T., Suda, S., Matsuzaki, H., Iwata, Y., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009260 · Cited by 68 · cited 1×
“156 Suzuki, K. et al. (2010) Destruction of dopaminergic neurons in the midbrain by 6-”
Background
Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats
Eakin, K. C., Li, Y., Chiang, Y. H., Hoffer, B. J., Rosenheim, H. M., Greig, N. H., & Miller, J. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082016 · Cited by 67 · cited 2×
“60 Eakin, K. et al. (2013) Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLOS ONE 8, e82016 61 Greig, N.H. et al. (2014) Incretin mimetics as pharmacologic tools to elucidate”
Background
A role for sphingolipids in the pathophysiology of obesity-induced inflammation
Bikman, B. T. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0917-5 · Cited by 67 · cited 1×
“222 Bikman, B.T. (2012) A role for sphingolipids in the pathophysiology of obesity-”
Background
Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-β peptide (1–42)
Qin, Z., Sun, Z., Huang, J., Hu, Y., Wu, Z., & Mei, B. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.08.047 · Cited by 66
GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats
Sharma, A. N., Ligade, S. S., Sharma, J. N., Shukla, P., Elased, K. M., & Lucot, J. B. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9591-7 · Cited by 66
RTP801/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disorders
Canal, M., Romaní-Aumedes, J., Martín‐Flores, N., PÃ©rez-FernÃ¡ndez, V., & Malagelada, C. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00313 · Cited by 65 · cited 2×
“26, 1680–1689 237 Canal, M. et al. (2014) RTP801/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disorders.”
Background
Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation
Chen, S., An, F.-M., Yin, L., Liu, A.-R., Yin, D.-K., Yao, W.-B., & Gao, X.-D. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.10.038 · Cited by 64
Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium
DeNicola, M., Du, J., Wang, Z., Yano, N., Zhang, L., Wang, Y., Qin, G., Zhuang, S., & Zhao, T. C. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00109.2014 · Cited by 63 · cited 1×
“20, 1557–1568 85 DeNicola, M. et al. (2014) Stimulation of glucagon-like peptide-1 receptor through”
Exenatide and weight loss
Bradley, D. P., Kulstad, R., & Schoeller, D. A. (2010) · Nutrition · doi:10.1016/j.nut.2009.07.008 · Cited by 62
Neuroprotective effects of geniposide on Alzheimer’s disease pathology
Liu, W., Li, G., Hölscher, C., & Li, L. (2015) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0005 · Cited by 62

Flagged first, then by citations

3 of the 258 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Ribeiro, 2012, Sitagliptin does not protect against MPTP-induced dopaminergic striatal toxicity, pA2 Online, 10

Sorted by citations

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing
Cunnane, S. C., Trushina, E., Morland, C., Prigione, A., Casadesus, G., Andrews, Z. B., Beal, M. F., Bergersen, L. H., Brinton, R. D., de la Monte, S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0072-x · Cited by 1,003
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Self-citation
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
“Injection of exendin-4 into rodents after endotoxin and mTP toxin-induced damage to the substantia nigra striatum could prevent the toxin-induced activation of microglia and inhibit the production of pro-inflammatory cytokines (70).”
Background
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
Lang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 384

See all 383

Authors: Athauda, D., & Foltynie, T.
Affiliations: National Hospital for Neurology and Neurosurgery (GB)
Corresponding author: Athauda, Dilan
ORCID: Athauda, Dilan
Foltynie, Thomas
Venue: Drug Discovery Today
Publisher: Elsevier BV
Published: 2016-05
Volume: 21
Issue: 5
Pages: 802-818
ISSN: 1359-6446 (ISSN-L)
DOI: 10.1016/j.drudis.2016.01.013
OpenAlex: W2270971263
Cited by: 383
References: 258
Citations by year: 2026: 38 · 2025: 51 · 2024: 53 · 2023: 31 · 2022: 46 · 2021: 34 · 2020: 42 · 2019: 32 · 2018: 29 · 2017: 19 · 2016: 8
FWCI: 4.07
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Drug Discovery Today (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: Michael J. Fox Foundation, Brain Research Trust, Cure Parkinson's Trust, Parkinson's UK
European Commission (FP7)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords: GLP-1 receptor, GLP-1 receptor agonists, Parkinson's disease, neuroprotection, exenatide, Parkinson's disease dementia, Alzheimer's disease, mechanism of action, therapeutic target
MeSH terms: Glucagon-Like Peptide-1 Receptor, Alzheimer Disease, Animals, Humans, Insulin Resistance, Learning, Mitochondria, Parkinson Disease, Signal Transduction, Proto-Oncogene Proteins c-akt, Glucagon-Like Peptide 1, Neurogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks